


## AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I




wherein

$R_a$  is H, or  $C_{1-4}$ -alkyl, or  $C_{1-4}$ -alkyl substituted by OH,  $NH_2$ ,  $NHC_{1-4}$ -alkyl or  $N(di-C_{1-4}$ -alkyl) $_2$ ;

one of  $R_b$ ,  $R_c$ ,  $R_d$  and  $R_e$  is halogen,  $C_{1-4}$ -alkoxy, or  $C_{1-4}$ -alkyl, and the other three substituents are H; or  $R_b$ ,  $R_c$ ,  $R_d$  and  $R_e$  are all H; and

$R$  is a radical of formula (a)



wherein

$R_1$  is  $-(CH_2)_n-NR_3R_4$ , wherein

each of  $R_3$  and  $R_4$ , independently, is H or  $C_{1-4}$ -alkyl; or  $R_3$  and  $R_4$  form together with the nitrogen atom to which they are bound a heterocyclic residue;

$n$  is 0, 1 or 2; and

$R_2$  is H, halogen,  $C_{1-4}$ -alkyl,  $CF_3$ , OH, SH,  $NH_2$ , or  $NO_2$ ,  $C_{1-4}$ -alkoxy,  $C_{1-4}$ -alkylthio,  $NHC_{1-4}$ -alkyl,  $N(di-C_{1-4}$ -alkyl) $_2$  or CN;

or a salt thereof.

2. (Currently amended) A compound according to Claim 1, wherein  $R_a$  is H or methyl; one of  $R_b$ ,  $R_c$ ,  $R_d$  and  $R_e$  is methyl or ethyl and the other three substituents are H; or  $R_b$ ,  $R_c$ ,  $R_d$  and  $R_e$  are all H;  $R_2$  is H, Cl, methyl or  $NO_2$ ;  $n$  is 1; and each of  $R_3$  and  $R_4$ , independently, is H, methyl, ethyl or *i*-propyl; or  $R_3$  and  $R_4$  form together with the nitrogen atom to which they are bound a heterocyclic residue; or a salt thereof.

3. (Currently amended) A compound according to Claim 1, which is selected from 3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro 6-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(6-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione:

3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(2-Chloro-6-methylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

3-(6-Aminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;

3-(6-Aminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;

or and a salt of any thereof.


4. (Currently amended) A compound according to Claim 1, in free form or in a pharmaceutically-acceptable salt form, for use as a pharmaceutical.

5. and 6. (Canceled)

7. (Withdrawn by the Examiner)

8. (Currently amended) A pharmaceutical combination comprising a compound according to Claim 1, in free form or in a pharmaceutically-acceptable salt form, and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic. antiproliferative and anti-diabetic agents.

9. (Currently amended) A process for the production of the compound of formula I according to Claim 1, which process comprises reacting a compound of formula II



wherein R<sub>a</sub>; R<sub>b</sub>; R<sub>c</sub>; R<sub>d</sub> and R<sub>e</sub> are as defined in Claim 1,  
with a compound of formula III



wherein R is as defined in Claim 1 ~~and claim 2~~,  
and, where required, converting the resulting compound of formula I obtained in  
free form to a salt form or *vice versa*, as appropriate.

10. (Withdrawn by the Examiner)